Featured Clinical Leader Editorial
-
The Key Differences Between Expanded Access Programs And Investigator Sponsored Trials
3/6/2024
Expanded access programs (EAPs) and investigator sponsored trials (ISTs) play significant roles. While both aim to provide patients with access to investigational therapies, they operate under distinct frameworks and serve different purposes. Understanding their differences from traditional clinical trials is crucial from an investigational medicine product and supply chain perspective.
-
2 Ways To Encourage Clinical Trial Investor Funding
3/6/2024
Consider these two promising funding models that balance risk with reward: trial-specific fundraising and staged funding release.
-
Advancing Alzheimer's Treatment Means Using The Best Biomarker(s) — But Which?
2/26/2024
As the Alzheimer's disease community grapples with the intricacies of biomarkers, trial outcomes, and the need for more precise diagnostic tools, the path forward requires a significant shift, redefining expectations and embracing a more comprehensive understanding of the disease.
-
4 Drug Development Strategies To Accelerate Commercialization
2/24/2024
Given the extenuated clinical trial timelines, every chance to shave off time, save money, and obtain regulatory approval is one worth taking. Discover four ways to accelerate your therapy’s path to commercialization.
-
Post-Pandemic Planning: Using Direct-To-Patient Deliveries For Supply Chain Management
2/23/2024
UCB Vice President – Head of Global Clinical Science and Operations Tero Laulajainen gets us up to speed on direct-to-patient (DTP) trials and how UCB is leveraging it today.
-
Site Feasibility Tips For Cell And Gene Therapy Clinical Trials
2/22/2024
Site feasibility assessment can be challenging. Therefore, it’s essential to have a solid understanding of the regulatory obligations for investigators and sites when it comes to choosing each.
-
4 Things I Learned At SCOPE 2024
2/21/2024
The Summit for Clinical Ops Executives (SCOPE) ran from Feb. 11-4. Discover four things Executive Editor Abby Proch learned at the annual event.
-
How To Improve Your Clinical Finance Function
2/16/2024
In the finale of this three-part series on clinical finance, IGM Biosciences Vice President, Financial Planning & Analysis Chris Chan discusses how to leverage the role of clinical finance for clinical trial success.
-
Ramblings From A First-Time SCOPE Attendee
2/15/2024
Dan Schell, chief editor of Clinical Leader, discusses what sessions stood out to him and some of the KOLs he rubbed elbows with while attending his first SCOPE Summit.
-
Why Is Clinical Finance Important?
2/15/2024
In part two, IGM Biosciences Vice President, Financial Planning & Analysis Chris Chan explains just how important the role of clinical finance can be in bringing harmony and success into clinical research.